CONNECTA Therapeutics, an Inveready portfolio company, announces positive results from Phase I study of neurodevelopmental disorders drug candidate, CTH120

by Inveready Asset Management

CTH120 is an investigational drug that modulates neuroplasticity, a property of the brain affected in many neurodevelopmental disorders, including attention-deficit/hyperactivity disorder (ADHD), Down...

Read more

Connecta Therapeutics, the CRG and the IMIM receive €1.97 million from the Spanish National Innovation Agency to develop a treatment for fragile X syndrome

by Inveready Asset Management

The public-private consortium formed by the biotech company Connecta Therapeutics, the Centre for Genomic Regulation (CRG) and the Hospital del Mar Medical Research Institute (IMIM) has received a gra...

Read more

Connecta Therapeutics raises €1.7 M in a round led by Inveready to develop new treatment for fragile X syndrome

by Inveready Asset Management

Other participants in Connecta’s capital increase included CDTI, through the Innvierte program for innovative Spanish technology companies; the founders of Prous Institute for Biomedical Research, J...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Suma Capital strengthens Gestcompost to ...

by Suma Capital

Since Suma Capital’s entry in 2020, Gestcompost has quadrupled its E...

Photos Stream